Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors

This publication has 38 references indexed in Scilit:

• HER-2/neu expression in primary and metastatic breast cancer
  Breast Cancer Research and Treatment, 2008
• Breast Tumor Heterogeneity: Cancer Stem Cells or Clonal Evolution?
  Cell Cycle, 2007
• Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer
  Clinical Cancer Research, 2007
• Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis
  Breast Cancer Research and Treatment, 2006
• HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial
  Journal of Clinical Oncology, 2006
• HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
  2006
• Docetaxel, Cisplatin, and Trastuzumab As Primary Systemic Therapy for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced Breast Cancer
  Journal of Clinical Oncology, 2006
• Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab
  Breast Cancer Research and Treatment, 2005
• Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease
  British Journal of Cancer, 2005
• Comparison of HER‐2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma
  Cancer, 2005